Valeant completes $475 mln buy of PE-backed PreCision Dermatology
Canadian specialty pharmaceutical company Valeant Pharmaceuticals International Inc (TSX: VRX) has completed its previously announced purchase of PreCision Dermatology Inc, a developer and marketer of dermatology products. As reported by Reuters in February, the deal was valued at $475 million. Formed in 2010 as the result of the spin-out of Onset Therapeutics, a subsidiary of Collegium Pharmaceutical Inc, the Cumberland, Rhode Island-based PreCision was backed by U.S. private equity firms Boston Millennia Partners, Essex Woodlands, Frazier Healthcare and Westfield Capital Management.
8 July 2014•1 min read
